Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amneal Pharmaceuticals (AMRX), Immunovant (IMVT) and...

Analysts’ Top Healthcare Picks: Amneal Pharmaceuticals (AMRX), Immunovant (IMVT)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Royalty Pharma, with a price target of $62.00...

Current Quarter	$1.27	Next Quarter	$1.1
Current Year	$5.05	Next Year	$5.51
QoQ Growth	-13.4%	YoY Growth	+9.1%
3Y EPS CAGR	+1.6%	Target Price	$59.57
Consensus	Buy	Upside	+10.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RPRX	$53.98	-0.96%	1.14M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RPRX	$53.98	-1.0%	1.14M
3
4
5
6

RPRX

RPRX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Royalty Pharma plc Data in Excel

Get Royalty Pharma plc Data in Excel